Want to bring cutting-edge prostate cancer treatments to your patients? Don’t miss the PeerView Live Clinical Consults event at AUA2025 in Las Vegas, featuring expert discussions and real-world strategies. Register today!
For more information and to register for this CME/CE symposium, please visit: PeerView.comProstate2025-Live.
The expanding prostate cancer treatment landscape has afforded new opportunities to optimize patient outcomes through personalized therapy. Progress in the management of early-stage disease, including high-risk biochemical recurrence, has successfully extended the metastasis-free interval, while treatments such as hormonal therapies, PARP inhibitors, and radioligands have increased progression-free and overall survival in advanced-disease settings. What do urologists and other members of the cancer care team need to know to bring these advances to their patients in community practice?
In a PeerView Live Clinical Consults event, presented in partnership with ZERO Prostate Cancer, an expert faculty panel will provide the tools clinicians need to incorporate modern therapeutics into the care of patients at all stages of disease. With a focus on practical guidance and actionable strategies, the faculty will pair an update on the efficacy and safety evidence supporting approved and emerging treatment regimens with lively discussion of patient cases drawn from their own experiences. Attendees will learn best practices for identification of biochemical recurrence, implementation of genetic testing, team-based management of AEs, and promoting treatment adherence through patient education. Register today to join the experts at AUA in Las Vegas and get ready to bring personalized prostate cancer care into the real world!
This CME/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.
This activity has been developed in partnership with ZERO Prostate Cancer.
This activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).